The role of teicoplanin in the treatment of SARS-CoV-2 infection : A retrospective study in critically ill COVID-19 patients (Tei-COVID study)
© 2021 Wiley Periodicals LLC..
Teicoplanin has a potential antiviral activity expressed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was suggested as a complementary option to treat coronavirus disease 2019 (COVID-19) patients. In this multicentric, retrospective, observational research the aim was to evaluate the impact of teicoplanin on the course of COVID-19 in critically ill patients. Fifty-five patients with severe COVID-19, hospitalized in the intensive care units (ICUs) and treated with best available therapy were retrospectively analysed. Among them 34 patients were also treated with teicoplanin (Tei-COVID group), while 21 without teicoplanin (control group). Crude in-hospital Day-30 mortality was lower in Tei-COVID group (35.2%) than in control group (42.8%), however not reaching statistical significance (p = .654). No statistically significant differences in length of stay in the ICU were observed between Tei-COVID group and control group (p = .248). On Day 14 from the ICU hospitalization, viral clearance was achieved in 64.7% patients of Tei-COVID group and 57.1% of control group, without statistical difference. Serum C-reactive protein level was significantly reduced in Tei-COVID group compared to control group, but not other biochemical parameters. Finally, Gram-positive were the causative pathogens for 25% of BSIs in Tei-COVID group and for 70.6% in controls. No side effects related to teicoplanin use were observed. Despite several limitations require further research, in this study the use of teicoplanin is not associated with a significant improvement in outcomes analysed. The antiviral activity of teicoplanin against SARS-CoV-2, previously documented, is probably more effective at early clinical stages.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Journal of medical virology - 93(2021), 7 vom: 04. Juli, Seite 4319-4325 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ceccarelli, Giancarlo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
61036-62-2 |
|---|
| Anmerkungen: |
Date Completed 08.06.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.26925 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322324920 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322324920 | ||
| 003 | DE-627 | ||
| 005 | 20231225181811.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.26925 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1074.xml |
| 035 | |a (DE-627)NLM322324920 | ||
| 035 | |a (NLM)33675235 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ceccarelli, Giancarlo |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of teicoplanin in the treatment of SARS-CoV-2 infection |b A retrospective study in critically ill COVID-19 patients (Tei-COVID study) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Wiley Periodicals LLC. | ||
| 520 | |a Teicoplanin has a potential antiviral activity expressed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was suggested as a complementary option to treat coronavirus disease 2019 (COVID-19) patients. In this multicentric, retrospective, observational research the aim was to evaluate the impact of teicoplanin on the course of COVID-19 in critically ill patients. Fifty-five patients with severe COVID-19, hospitalized in the intensive care units (ICUs) and treated with best available therapy were retrospectively analysed. Among them 34 patients were also treated with teicoplanin (Tei-COVID group), while 21 without teicoplanin (control group). Crude in-hospital Day-30 mortality was lower in Tei-COVID group (35.2%) than in control group (42.8%), however not reaching statistical significance (p = .654). No statistically significant differences in length of stay in the ICU were observed between Tei-COVID group and control group (p = .248). On Day 14 from the ICU hospitalization, viral clearance was achieved in 64.7% patients of Tei-COVID group and 57.1% of control group, without statistical difference. Serum C-reactive protein level was significantly reduced in Tei-COVID group compared to control group, but not other biochemical parameters. Finally, Gram-positive were the causative pathogens for 25% of BSIs in Tei-COVID group and for 70.6% in controls. No side effects related to teicoplanin use were observed. Despite several limitations require further research, in this study the use of teicoplanin is not associated with a significant improvement in outcomes analysed. The antiviral activity of teicoplanin against SARS-CoV-2, previously documented, is probably more effective at early clinical stages | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ICU | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Teicoplanin | |
| 650 | 4 | |a glycopeptide | |
| 650 | 4 | |a intensive care unit | |
| 650 | 4 | |a pneumonia | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Teicoplanin |2 NLM | |
| 650 | 7 | |a 61036-62-2 |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Alessandri, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Borrazzo, Cristian |e verfasserin |4 aut | |
| 700 | 1 | |a Dell'Isola, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Ialungo, Anna Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Rastrelli, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Pelli, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Raponi, Giammarco |e verfasserin |4 aut | |
| 700 | 1 | |a Turriziani, Ombretta |e verfasserin |4 aut | |
| 700 | 1 | |a Ruberto, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Rocco, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Pugliese, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a d'Ettorre, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Venditti, Mario |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 93(2021), 7 vom: 04. Juli, Seite 4319-4325 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2021 |g number:7 |g day:04 |g month:07 |g pages:4319-4325 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.26925 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2021 |e 7 |b 04 |c 07 |h 4319-4325 | ||